Cargando…

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma

Promising antitumor activities of nivolumab, a fully humanized IgG4 inhibitor antibody against the programmed death‐1 protein, were suggested in previous phase 1 studies. The present phase 2, single‐arm study (JAPIC‐CTI #111681) evaluated the antitumor activities of nivolumab and explored its predic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamazaki, Naoya, Kiyohara, Yoshio, Uhara, Hisashi, Iizuka, Hajime, Uehara, Jiro, Otsuka, Fujio, Fujisawa, Yasuhiro, Takenouchi, Tatsuya, Isei, Taiki, Iwatsuki, Keiji, Uchi, Hiroshi, Ihn, Hironobu, Minami, Hironobu, Tahara, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448619/ https://www.ncbi.nlm.nih.gov/pubmed/28266140 http://dx.doi.org/10.1111/cas.13226

Ejemplares similares

Long‐term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2019)

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Five‐year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Uhara, Hisashi, et al.
Publicado: (2021)

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
por: Yokota, Kenji, et al.
Publicado: (2019)

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post‐marketing surveillance
por: Uhara, Hisashi, et al.
Publicado: (2022)

A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2022)

Phase I study of pegylated interferon‐alpha‐2b as an adjuvant therapy in Japanese patients with malignant melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2016)

Real‐world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance
por: Yamazaki, Naoya, et al.
Publicado: (2020)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma
por: Wakamatsu, Kazumasa, et al.
Publicado: (2020)

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

Myasthenic crisis and polymyositis induced by one dose of nivolumab
por: Kimura, Toshihiro, et al.
Publicado: (2016)

Clinical Significance of Serum Vascular Endothelial-Cadherin Levels in Inflammatory Skin Diseases
por: Kuriyama, Haruka, et al.
Publicado: (2014)

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)
por: Namikawa, Kenjiro, et al.
Publicado: (2017)

Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
por: Nakamura, Hajime, et al.
Publicado: (2023)

Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer
por: Koyama, Taiji, et al.
Publicado: (2021)

Systemic therapy for Asian patients with advanced BRAF V600‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (B‐CHECK‐RWD study)
por: Namikawa, Kenjiro, et al.
Publicado: (2023)

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
por: Inoue, Hiroyuki, et al.
Publicado: (2016)

Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trial
por: Tamura, Kenji, et al.
Publicado: (2019)

Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2019)

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
por: Nakamura, Yoshio, et al.
Publicado: (2016)

NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia
por: Kakiuchi, Seiji, et al.
Publicado: (2017)

Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma
por: Fujisawa, Yasuhiro, et al.
Publicado: (2019)

Salvage Reconstructive Surgery During Nivolumab Therapy for a Patient With Hypopharyngeal Cancer
por: Tsushima, Nayuta, et al.
Publicado: (2020)

Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)
por: Yamazaki, Naoya, et al.
Publicado: (2021)

Direct borylation of terrylene and quaterrylene
por: Kano, Haruka, et al.
Publicado: (2020)

Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab
por: Hara, Yoshihiro, et al.
Publicado: (2022)

Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
por: Ishii, Maki, et al.
Publicado: (2020)

Geographical Flushing of the Children's Face: A New Clinical Entity?
por: Jinnin, Masatoshi, et al.
Publicado: (2013)

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Treatable Subsets in Cancer of Unknown Primary Origin
por: Sumi, Hajime, et al.
Publicado: (2001)

Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma
por: Ogawa-Morita, Tomoko, et al.
Publicado: (2017)

Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma
por: Fujimura, Taku, et al.
Publicado: (2018)

Elucidation of Melanogenesis Cascade for Identifying Pathophysiology and Therapeutic Approach of Pigmentary Disorders and Melanoma
por: Hida, Tokimasa, et al.
Publicado: (2020)

Relationships among Student-Athletes’ Identity, Mental Health, and Social Support in Japanese Student-Athletes during the COVID-19 Pandemic †
por: Hagiwara, Goichi, et al.
Publicado: (2021)

Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan
por: Uhara, H., et al.
Publicado: (2017)

Endoscopic ultrasound findings and pathological features of pancreatic carcinoma in situ
por: Izumi, Yoshihiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q3iuu4o623ctl6r5ulglmfsovc